What is the ticker symbol for Aktis Oncology?

Aktis Oncology trades under the ticker AKTS on NASDAQ.

What sector does Aktis Oncology operate in?

Aktis Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AKTS in a portfolio?

PortView shows AKTS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Aktis Oncology (AKTS) Stock Analysis

NASDAQHealthcareBiotechnology

$26.23+0.92%

1-year price historyRange $15.19 – $32.23

52-week range$26.23

$14.72$34.19

What Aktis Oncology does

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Key metrics

Market cap

$1.40B

P/E (TTM)

-1.41

EPS (TTM)

$-18.57

Beta

0.45

Dividend yield

0.00%

Revenue / share

$0.15

50-day avg

$25.72

200-day avg

$21.41

52-week high

$34.19

52-week low

$14.72

CEO

Matthew Roden

ETFs linked to AKTS

Broad-market and Healthcare sector ETFs an investor holding Aktis Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how AKTS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze AKTS in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Aktis Oncology?: Aktis Oncology trades under the ticker AKTS on NASDAQ.
Which exchange is AKTS listed on?: AKTS is listed on NASDAQ.
What sector does Aktis Oncology operate in?: Aktis Oncology is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze AKTS in a portfolio?: PortView shows AKTS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.